peptide content raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-04 and is reviewed periodically as new material appears.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
=== Cardiovascular system === Women are less impacted by heart disease due to vasculo-protective action of estrogen which helps in preventing atherosclerosis. It also helps in maintaining the delicate balance between fighting infections and protecting arteries from damage thus lowering the risk of cardiovascular disease. During pregnancy, high levels of estrogens increase coagulation and the risk of venous thromboembolism. Estrogens have been shown to upregulate the peptide hormone adropin, increase platelet adhesiveness, and increase the circulating level of coagulation factors 2, 7, 9, and 10, as well as plasminogens. They also decrease antithrombin III, which suppresses parts of the coagulation system.
=== Approval process and advocacy === In June 2010, a federal advisory panel to the US Food and Drug Administration (FDA) unanimously voted against recommending approval of flibanserin, citing an inadequate risk-benefit ratio. The committee acknowledged the validity of hypoactive sexual desire as a diagnosis, but expressed concern with the drug's side effects and insufficient evidence for efficacy, especially the drug's failure to show a statistically significant effect on the co-primary endpoint of sexual desire. Ahead of the votes, Boehringer Ingelheim had mounted a publicity campaign to promote the controversial disorder of "hypoactive sexual desire". In 2010, the FDA issued a Complete Response Letter, stating that the new drug application could not be approved in its current form. The letter cited several concerns, including the failure to demonstrate a statistical effect on the co-primary endpoint of sexual desire and overly restrictive entry criteria for the two phase III trials. The FDA recommended performing a new phase III trial with less restrictive entry criteria. In October 2010, Boehringer announced that it would discontinue its development of flibanserin in light of the FDA's decision. Sprout responded to the FDA's cited deficiencies and refiled the new drug application in 2013. The submission included data from a new phase III trial and several phase I drug-drug interaction studies. The FDA again refused the application, citing an uncertain risk/benefit ratio.
=== 1974 === February 7: Grenada becomes independent from the UK. April 25: Portuguese Armed Forces revolt against the authoritarian regime of Estado Novo. Fascism in Portugal officially ended, and Spain became the last and only fascist country that still stood at the time. June 26: NATO holds a summit in Brussels, the first one since 1957 to be held. June 28: The Moscow Summit begins. July 20: Turkey invaded Cyprus after a coup d'état conducted by the Greek junta. July 24: The Greek Junta gives up its power after the Cypriot Junta government of the 1974 Cypriot coup d'état fell on July 23. This initiated a new period of Greek history known as Metapolitefsi, which led to the restoration of democracy in Greece. August 9: Gerald Ford becomes President of the United States upon the resignation of Nixon. September 4: The United States and East Germany begin diplomatic relations. September 12: The pro-Western monarch of Ethiopia, Haile Selassie, is ousted by a Marxist military junta known as the Derg. November 24: The SALT II Agreement is drafted at the Vladivostok Summit Meeting on Arms Control. December 8: Following a referendum, Greece voted to confirm their abolition of their monarchy the previous year.
The first comprehensive analysis of the city's tens of thousands of abandoned and dilapidated buildings took place in the spring of 2014. It found that around 50,000 of the city's 261,000 structures were abandoned, with over 9,000 structures bearing fire damage. It further recommended the demolition of 5,000 of these structures. Between 2000 and 2010, Detroit lost a quarter of its population. More people left Detroit during this time—237,500—than fled New Orleans after Hurricane Katrina—140,000. However, from 2010 to 2018, Detroit saw the biggest growth in racial diversity of any city analyzed by a US news study. This is not the racial diversity most other cities experienced. Opposite of the white flight most cities experienced, where whites fled cities for safer suburbs, Detroit saw an influx of white residents into the downtown and midtown areas. The Midtown and downtown areas have increasing population density, while African American neighborhoods remain without good access to public services. The city's poverty rate remains several times higher than the national average.
=== Saliva tests === In 2008, scientists announced that the more cost effective saliva testing could eventually replace some blood tests, as saliva contains 20% of the proteins found in blood. Saliva testing may not be appropriate or available for all markers. For example, lipid levels cannot be measured with saliva testing.
Sources: en.wikipedia.org
=== Total chemical synthesis === A complete organic synthesis pathway for the pyoverdine produced by P. aeruginosa strain PAO1 has been reported using solid-phase peptide synthesis. This protocol yielded pyoverdine at high yield (~48%) and is expected to substantially increase the ability of scientists to generate targeted derivatives on the pyoverdine scaffold and to facilitate the creation of siderophores with antimicrobial warheads.
=== Brand names === Numorphan (suppository and injectable solution) Opana ER (extended-release tablet): June 2017 FDA removal request due to rates of IV abuse. Opana IR (immediate-release tablet) O-Morphon in Bangladesh by Ziska pharmaceutical ltd. The brand name Numorphan is derived by analogy to the Nucodan name for an oxycodone product (or vice versa) as well as Paramorphan/Paramorfan for dihydromorphine and Paracodin (dihydrocodeine). The only commercially available salt of oxymorphone in most of the world at this time is the hydrochloride, which has a free base conversion ratio of 0.891, and oxymorphone hydrochloride monohydrate has a factor of 0.85. Generic pill markings are ATV10/APO; HK10 (10 mgs) oblong white and ATV20/APO; HK20 (20 mgs) oblong white.
=== Legal status === Takeda filed a marketing authorisation application in the European Union on 7 March 2013 and a biologic license application (BLA) with the U.S. Food and Drug Administration on 21 June 2013 for both Crohn's disease and ulcerative colitis. On 4 September 2013, vedolizumab was given a Priority Review Status, which functions to expedite potential acceptance to market. In March 2014, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for vedolizumab (brand name Entyvio). In May 2014, vedolizumab (Entyvio) was approved by the FDA for treatment of both moderate-to-severe ulcerative colitis and moderate-to-severe Crohn's disease. In May 2014, Entyvio was approved for medical use in the European Union. In April 2015, Health Canada approved Entyvio.
== See also == Gomashio – a type of furikake mostly consisting of cooked black sesame seeds and sea salt crystals Ochazuke – a soup made by sprinkling seasonings (such as furikake) and toppings over cooked rice, then covering with brewed green tea Shichimi – a chilli-based spice mixture similar to furikake mainly used on noodles, soups and gyūdon List of sesame seed dishes Chutney
== June 27, 1915 (Sunday) == Born: Grace Lee Boggs, American author and social activist, author of The Invading Socialist Society and The Next American Revolution; as Grace Chin Lee, in Providence, Rhode Island, United States (d. 2015)
Sources: en.wikipedia.org
=== Founding the Respect Party === Galloway wrote in an article for The Guardian at the end of October 2003 that he would soon be part of a coalition consisting of the "red, green, anti-war, Muslim and other social constituencies radicalised by the war." In January 2004, it emerged that Galloway would be working with the Socialist Workers Party in England and Wales, and others, under the name Respect – The Unity Coalition, generally referred to simply as "Respect". In the opinion of Nick Cohen of The Observer it was an "alliance ... between the Trotskyist far left and the Islamic far right." Galloway announced in December 2003 that he would not force a by-election and did not intend to contest the next general election in Glasgow. His Glasgow Kelvin seat was to be split between three constituencies for the next general election. In one of these, the new Glasgow Central constituency, Mohammad Sarwar, the first Muslim Labour MP, wanted to be selected as the candidate. Galloway chose not to challenge him, announcing this decision at the end of May 2004 in his Mail on Sunday column.
Handbook for Coroners, police officials, military policemen was written by the Austrian criminal jurist Hans Gross in 1893, and is generally acknowledged as the birth of the field of criminalistics. The work combined in one system fields of knowledge that had not been previously integrated, such as psychology and physical science, and which could be successfully used against crime. Gross adapted some fields to the needs of criminal investigation, such as crime scene photography. He went on to found the Institute of Criminalistics in 1912, as part of the University of Graz' Law School. This Institute was followed by many similar institutes all over the world. In 1909, Archibald Reiss founded the Institut de police scientifique of the University of Lausanne (UNIL), the first school of forensic science in the world. Dr. Edmond Locard, became known as the "Sherlock Holmes of France". He formulated the basic principle of forensic science: "Every contact leaves a trace", which became known as Locard's exchange principle. In 1910, he founded what may have been the first criminal laboratory in the world, after persuading the Police Department of Lyon (France) to give him two attic rooms and two assistants. Symbolic of the newfound prestige of forensics and the use of reasoning in detective work was the popularity of the fictional character Sherlock Holmes, written by Arthur Conan Doyle in the late 19th century. He remains a great inspiration for forensic science, especially for the way his acute study of a crime scene yielded small clues as to the precise sequence of events.
Toxic Harmful; having to do with poison. Transcutaneous electric nerve stimulation (TENS) A treatment for painful neuropathy. Trauma Triglyceride Twenty-four hour urine The total amount of a person's urine for a 24-hour period. Diabetes mellitus type 1 It is a chronic condition in which the pancreas makes little or no insulin because the beta cells have been destroyed. About two-thirds of body cells require insulin to absorb glucose and in its absence, they will not be able to use the glucose (blood sugar) for energy. Type 1 diabetes usually comes on abruptly, although the damage to the beta cells may begin much earlier. Typical signs of Type 1 diabetes are a great thirst, hunger, a need to urinate often, and loss of weight. To treat the disease, the person must inject insulin and test blood glucose frequently. Type 1 diabetes usually occurs in children and adults who are under age 30. This type of diabetes used to be known as "insulin-dependent diabetes," "juvenile diabetes," "juvenile-onset diabetes" and "ketosis-prone diabetes." Diabetes mellitus type 2 The most common form of diabetes mellitus; about 90 to 95 percent of people who have diabetes in the developed world have Type 2 diabetes. Unlike Type 1 diabetes, in which the pancreas makes no insulin, people with Type 2 diabetes produce some insulin, sometimes even large amounts. However, either their bodies do not produce enough insulin or their body cells are resistant to insulin (see Insulin Resistance). People with Type 2 diabetes can often control their condition by losing weight through diet and exercise.
Isotope masses from: Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Isotopic compositions and standard atomic masses from: de Laeter, John Robert; Böhlke, John Karl; De Bièvre, Paul; Hidaka, Hiroshi; Peiser, H. Steffen; Rosman, Kevin J. R.; Taylor, Philip D. P. (2003). "Atomic weights of the elements. Review 2000 (IUPAC Technical Report)". Pure and Applied Chemistry. 75 (6): 683–800. doi:10.1351/pac200375060683. Wieser, Michael E. (2006). "Atomic weights of the elements 2005 (IUPAC Technical Report)". Pure and Applied Chemistry. 78 (11): 2051–2066. doi:10.1351/pac200678112051. "News & Notices: Standard Atomic Weights Revised". International Union of Pure and Applied Chemistry. 19 October 2005. Half-life, spin, and isomer data selected from the following sources. G. Audi; A. H. Wapstra; C. Thibault; J. Blachot; O. Bersillon (2003). "The NUBASE evaluation of nuclear and decay properties" (PDF). Nuclear Physics A. 729 (1): 3–128. Bibcode:2003NuPhA.729....3A. doi:10.1016/j.nuclphysa.2003.11.001. Archived from the original (PDF) on 2011-07-20. National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.
Insulin is an endogenous hormone, which is produced by the pancreas. The insulin protein has been highly conserved across evolutionary time, and is present in both mammals and invertebrates. The insulin/insulin-like growth factor signalling pathway (IIS) has been extensively studied in species including nematode worms (e.g.C. elegans), flies (Drosophila melanogaster) and mice (Mus musculus). Its mechanisms of action are highly similar across species. Both type 1 diabetes and type 2 diabetes are marked by a loss of pancreatic function, though to differing degrees. People who are affected with diabetes are referred to as diabetics. Many diabetics require an exogenous source of insulin to keep their blood sugar levels within a safe target range. In 1916, Nicolae C. Paulescu (1869–1931) succeeded in developing an aqueous pancreatic extract that normalized a diabetic dog. In 1921, he published 4 papers in the Society of Biology in Paris centering on the successful effects of the pancreatic extract in diabetic dogs. Research on the Role of the Pancreas in Food Assimilation by Paulescu was published in August 1921 in the Archives Internationales de Physiologie, Liège, Belgium. Initially, the only way to obtain insulin for clinical use was to extract it from the pancreas of another creature. Animal glands were obtainable as a waste product of the meatpacking industry. Insulin was derived primarily from cows (bovine) (Thorburn Brailsford Robertson (Australia); Eli Lilly and Company (USA)) and pigs (porcine) (Nordisk Insulinlaboratorium).
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.